Fate Therapeutics (FATE) Non-Current Debt (2012 - 2019)
Fate Therapeutics' (FATE) quarterly Non-Current Debt came in at $9.5 million in Q2 2019, down 26.23% YoY from $12.8 million in Q2 2018, and down 13.59% on a QoQ basis from $11.0 million in Q1 2019.
Fate Therapeutics (FATE) Non-Current Debt (2012 - 2019) Analysis & Trends
Fate Therapeutics (FATE) has 8 years of Non-Current Debt data on file, last reported at $9.5 million in Q2 2019.
- Quarterly Non-Current Debt fell 26.23% year-over-year to $9.5 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $9.5 million (down 26.23% YoY) and the FY2018 annual result came in at $12.4 million, down 15.95% from the prior year.
- Non-Current Debt retreated to $9.5 million in Q2 2019, from $11.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $16.4 million in Q1 2015 to a low of $2.5 million in Q4 2016.
- A 5-year average of $10.7 million and a median of $11.3 million in 2018 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2016 — Non-Current Debt tumbled 76.6% — and 2017, when it surged 492.08%.
- Tracing FATE's Non-Current Debt over 5 years: stood at $10.7 million in 2015, then plunged by 76.6% to $2.5 million in 2016, then surged by 492.08% to $14.8 million in 2017, then decreased by 15.95% to $12.4 million in 2018, then dropped by 23.92% to $9.5 million in 2019.
- The last three Non-Current Debt figures came in at $9.5 million (Q2 2019), $11.0 million (Q1 2019), and $12.4 million (Q4 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 9.47 Mn |
| Mar 31, 2019 | 10.96 Mn |
| Dec 31, 2018 | 12.45 Mn |
| Sep 30, 2018 | 11.60 Mn |
| Jun 30, 2018 | 12.84 Mn |
| Mar 31, 2018 | 14.07 Mn |
| Dec 31, 2017 | 14.81 Mn |
| Sep 30, 2017 | 14.79 Mn |
| Jun 30, 2017 | 6.68 Mn |
| Mar 31, 2017 | 8.75 Mn |
| Dec 31, 2016 | 2.50 Mn |
| Sep 30, 2016 | 4.61 Mn |
| Jun 30, 2016 | 6.68 Mn |
| Mar 31, 2016 | 8.70 Mn |
| Dec 31, 2015 | 10.69 Mn |
| Sep 30, 2015 | 12.64 Mn |
| Jun 30, 2015 | 14.54 Mn |
| Mar 31, 2015 | 16.41 Mn |
| Dec 31, 2014 | 18.07 Mn |
| Sep 30, 2014 | 9.39 Mn |